Product Information
INVEGA SUSTENNA 156 MG/ML SYRG is a brand product labeled by Janssen Pharmaceuticals Inc., priced at $2337.7083 per ML under NDC 50458056301. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jul 31, 2009.
Strength
156 mg/mL
Manufacturer
Janssen Pharmaceuticals Inc.NDC
50458056301
Classification
Brand
Dosage Form
INJECTION
Route
INTRAMUSCULAR
Effective Date
9/23/2026
Active Ingredients
PALIPERIDONE PALMITATEApproval Type
New Drug (NDA)
FDA Application
NDA022264FDA Approved
7/31/2009
On Market Since
7/31/2009
Pharmacological Classes
Price Statistics
The NADAC for INVEGA SUSTENNA 156 MG/ML SYRG has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 103.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2337.7083 per ML |
|---|---|
| All-time high | $2339.6450 (May 13, 2026) |
| All-time low | $1146.8243 (Nov 28, 2013) |
| 52-week high | $2339.6450 |
| 52-week low | $2283.7597 |
| Median price | $1797.6034 |
| Average price | $1780.0852 |
| Largest weekly change | +6.9% (Jan 16, 2019) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the paliperidone palmitate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Janssen Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
paliperidone palmitate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of INVEGA SUSTENNA 156 MG/ML SYRG?
The current National Average Drug Acquisition Cost (NADAC) for INVEGA SUSTENNA 156 MG/ML SYRG, manufactured by Janssen Pharmaceuticals Inc., is $2337.7083 per ML (NDC 50458056301), effective Sep 30, 2026.
How has the price of INVEGA SUSTENNA 156 MG/ML SYRG changed over time?
Over the history we have for it, the NADAC for INVEGA SUSTENNA 156 MG/ML SYRG has risen 103.8%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for INVEGA SUSTENNA 156 MG/ML SYRG?
Since Nov 28, 2013, the NADAC for INVEGA SUSTENNA 156 MG/ML SYRG has ranged from a low of $1146.8243 (Nov 28, 2013) to a high of $2339.6450 (May 13, 2026), with a median of $1797.6034 per ML.
Are there cheaper alternatives to INVEGA SUSTENNA 156 MG/ML SYRG?
No other NADAC-published product currently shares the active ingredient and strength of INVEGA SUSTENNA 156 MG/ML SYRG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures INVEGA SUSTENNA 156 MG/ML SYRG?
INVEGA SUSTENNA 156 MG/ML SYRG (NDC 50458056301) is labeled by Janssen Pharmaceuticals Inc., and CMS classifies it as a brand product.